The label for Xofluza (baloxavir marboxil) has been extended to include the treatment of uncomplicated flu infections in children aged one year and over, a particularly vulnerable group of patients, as well as post-exposure prophylaxis in those who are in close contact with an infected individual.
Use of Xofluza as post-exposure prophylaxis can help prevent influenza spreading in households and workplaces, and help patients recover more quickly, helps reduce the societal burden of the infectious disease, said Roche in a statement.
